Skip to main content

Advertisement

SpringerLink
Log in

Management of infection and febrile neutropenia in patients with solid cancer

  • Clinical Guides in Oncology
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

An expert group from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC, for its acronym in Spanish) and the Spanish Society of Medical Oncology (SEOM, for its acronym in Spanish) have reviewed the main aspects to be considered when evaluating patients with solid cancer and infectious complications contained in this article. Recommendations have, therefore, been put forth regarding the prophylaxis of the most prevalent infections in these patients, the use of vaccines, measures to control infection through vascular catheters, and preventing infection in light of certain surgical maneuvers. The following is a revision of the criteria for febrile neutropenia management and the use of colony-stimulating factors and closes with several guidelines for treating the cancer patient with serious infection. The document concludes with a series of measures to control hospital infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Prevention and treatment of cancer-related infections. Version 1.2013. (2014). http://oralcancerfoundation.org/treatment/pdf/infections.pdf

  2. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309–18. doi:10.1093/cid/cit816.

    Article  PubMed  Google Scholar 

  3. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. (2011);60:(2):1–64 (pii: rr6002a1). http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21293327

  4. EASL. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50(2):227–42. doi:10.1016/j.jhep.2008.10.001.

    Article  Google Scholar 

  5. Castellano G, Manzano ML. Tratamiento y profilaxis de la hepatitis B en pacientes inmunosuprimidos. Gastroenterol Hepatol. 2012;35(Espec Congr 1):1–19.

    Google Scholar 

  6. Hwang JP, Somerfield MR, Alston-Johnson DE, Cryer DR, Feld JJ, Kramer BS, et al. Hepatitis B virus screening for patients with cancer before therapy: american society of clinical oncology provisional clinical opinion update. J Clin Oncol. 2015;33(19):2212–20. doi:10.1200/JCO.2015.61.3745.

    Article  PubMed  Google Scholar 

  7. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. (2000);49(RR-6):1–51. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10881762

  8. Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin Infect Dis. 2006;42(11):1592–5. doi:10.1086/503917.

    Article  PubMed  Google Scholar 

  9. Menzies D, Sterling TR. Treatment of Mycobacterium tuberculosis infection: time to get a move on? Ann Intern Med. 2014;161(6):449–50. doi:10.7326/M14-1719.

    Article  PubMed  Google Scholar 

  10. Person AK, Pettit AC, Sterling TR. Diagnosis and treatment of latent tuberculosis infection: an update. Curr Respir Care Rep. 2013;2(4):199–207. doi:10.1007/s13665-013-0064-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Redelman-Sidi G, Sepkowitz KA. IFN-gamma release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med. 2013;188(4):422–31. doi:10.1164/rccm.201209-1621CI.

    Article  CAS  PubMed  Google Scholar 

  12. Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev. 2013;7:CD007545. doi:10.1002/14651858.CD007545.pub2.

    PubMed  Google Scholar 

  13. Stagg HR, Zenner D, Harris RJ, Munoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med. 2014;161(6):419–28. doi:10.7326/M14-1019.

    Article  PubMed  Google Scholar 

  14. Lorente L, Henry C, Martin MM, Jimenez A, Mora ML. Central venous catheter-related infection in a prospective and observational study of 2,595 catheters. Crit Care. 2005;9(6):R631–5. doi:10.1186/cc3824.

    Article  PubMed  PubMed Central  Google Scholar 

  15. O’Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis. 2011;52(9):e162–93. doi:10.1093/cid/cir257.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Schiffer CA, Mangu PB, Wade JC, Camp-Sorrell D, Cope DG, El-Rayes BF, et al. Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31(10):1357–70. doi:10.1200/JCO.2012.45.5733.

    Article  PubMed  Google Scholar 

  17. Ranson MR, Oppenheim BA, Jackson A, Kamthan AG, Scarffe JH. Double-blind placebo controlled study of vancomycin prophylaxis for central venous catheter insertion in cancer patients. J Hosp Infect. 1990;15(1):95–102 0195-6701(90)90025-J [pii].

    Article  CAS  PubMed  Google Scholar 

  18. Banerjee S, Shen B, Baron TH, Nelson DB, Anderson MA, Cash BD, et al. Antibiotic prophylaxis for GI endoscopy. Gastrointest Endosc. 2008;67(6):791–8. doi:10.1016/j.gie.2008.02.068.

    Article  PubMed  Google Scholar 

  19. Jain NK, Larson DE, Schroeder KW, Burton DD, Cannon KP, Thompson RL, et al. Antibiotic prophylaxis for percutaneous endoscopic gastrostomy. A prospective, randomized, double-blind clinical trial. Ann Intern Med. 1987;107(6):824–8.

    Article  CAS  PubMed  Google Scholar 

  20. Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis. 1993;17(Suppl 2):S416–22.

    Article  PubMed  Google Scholar 

  21. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82(9):1052–9. doi:10.4065/82.9.1052.

    Article  CAS  PubMed  Google Scholar 

  22. Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1987;316(26):1627–32. doi:10.1056/NEJM198706253162604.

    Article  CAS  PubMed  Google Scholar 

  23. Colby C, McAfee S, Sackstein R, Finkelstein D, Fishman J, Spitzer T. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;24(8):897–902. doi:10.1038/sj.bmt.1702004.

    Article  CAS  PubMed  Google Scholar 

  24. DeMasi JM, Cox JA, Leonard D, Koh AY, Aquino VM. Intravenous pentamidine is safe and effective as primary pneumocystis pneumonia prophylaxis in children and adolescents undergoing hematopoietic stem cell transplantation. Pediatr Infect Dis J. 2013;32(9):933–6. doi:10.1097/INF.0b013e318292f560.

    Article  PubMed  Google Scholar 

  25. Marras TK, Sanders K, Lipton JH, Messner HA, Conly J, Chan CK. Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation. Transpl Infect Dis. 2002;4(2):66–74 (pii: 0o008).

    Article  CAS  PubMed  Google Scholar 

  26. Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev. 2004;17(1):208–17.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Martinez-Perez A, Norman FF, Monge-Maillo B, Perez-Molina JA, Lopez-Velez R. An approach to the management of Trypanosoma cruzi infection (Chagas’ disease) in immunocompromised patients. Expert Rev Anti Infect Ther. 2014;12(3):357–73. doi:10.1586/14787210.2014.880652.

    Article  CAS  PubMed  Google Scholar 

  28. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158–67. doi:10.1200/JCO.2006.08.8823.

    Article  CAS  PubMed  Google Scholar 

  29. Crawford J, Caserta C, Roila F. Hematopoietic growth factors: ESMO clinical practice guidelines for the applications. Ann Oncol. 2010;21(Suppl 5):v248–51. doi:10.1093/annonc/mdq195.

    Article  PubMed  Google Scholar 

  30. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56–93. doi:10.1093/cid/cir073.

    Article  PubMed  Google Scholar 

  31. Berghmans T, Paesmans M, Lafitte JJ, Mascaux C, Meert AP, Jacquy C, et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer. 2002;10(3):181–8. doi:10.1007/s00520-001-0312-5.

    Article  CAS  PubMed  Google Scholar 

  32. Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23(18):4198–214. doi:10.1200/JCO.2005.05.645.

    Article  CAS  PubMed  Google Scholar 

  33. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258–66. doi:10.1002/cncr.21847.

    Article  PubMed  Google Scholar 

  34. Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005;353(10):988–98. doi:10.1056/NEJMoa050078.

    Article  CAS  PubMed  Google Scholar 

  35. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005;142(12 Pt 1):979–95 (pii: 142/12_Part_1/979).

    Article  PubMed  Google Scholar 

  36. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353(10):977–87. doi:10.1056/NEJMoa044097.

    Article  CAS  PubMed  Google Scholar 

  37. Bow EJ. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis. 2011;24(6):545–53. doi:10.1097/QCO.0b013e32834cf054.

    Article  CAS  PubMed  Google Scholar 

  38. Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis. 1995;20(3):557–60 (discussion 561–553).

    Article  CAS  PubMed  Google Scholar 

  39. Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31(6):794–810. doi:10.1200/JCO.2012.45.8661.

    Article  PubMed  Google Scholar 

  40. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother. 1994;38(4):681–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Neumann S, Krause SW, Maschmeyer G, Schiel X, von Lilienfeld-Toal M. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2013;92(4):433–42. doi:10.1007/s00277-013-1698-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41(9):1254–60. doi:10.1086/496986.

    Article  CAS  PubMed  Google Scholar 

  43. Cullen M, Baijal S. Prevention of febrile neutropenia: use of prophylactic antibiotics. Br J Cancer. 2009;101(Suppl 1):S11–4. doi:10.1038/sj.bjc.6605270.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Tjan-Heijnen VC, Postmus PE, Ardizzoni A, Manegold CH, Burghouts J, van Meerbeeck J, et al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol. 2001;12(10):1359–68.

    Article  CAS  PubMed  Google Scholar 

  45. Mayordomo JI, Lopez A, Vinolas N, Castellanos J, Pernas S, Domingo Alonso J, et al. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin. 2009;25(10):2533–42. doi:10.1185/03007990903209563.

    Article  PubMed  Google Scholar 

  46. Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol. 2006;24(25):4129–34. doi:10.1200/JCO.2005.03.9909.

    Article  CAS  PubMed  Google Scholar 

  47. Carmona-Bayonas A, Gomez J, Gonzalez-Billalabeitia E, Canteras M, Navarrete A, Gonzalvez ML, et al. Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients. Br J Cancer. 2011;105(5):612–7. doi:10.1038/bjc.2011.284.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med. 1988;148(12):2561–8.

    Article  CAS  PubMed  Google Scholar 

  49. Teuffel O, Ethier MC, Alibhai SM, Beyene J, Sung L. Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. Ann Oncol. 2011;22(11):2358–65. doi:10.1093/annonc/mdq745.

    Article  CAS  PubMed  Google Scholar 

  50. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580–637. doi:10.1097/CCM.0b013e31827e83af.

    Article  PubMed  Google Scholar 

  51. Carmona-Bayonas A, Jimenez-Fonseca P, Virizuela Echaburu J, Antonio M, Font C, Biosca M, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol. 2015;33(5):465–71. doi:10.1200/JCO.2014.57.2347.

    Article  PubMed  Google Scholar 

  52. Kern WV, Marchetti O, Drgona L, Akan H, Aoun M, Akova M, et al. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy—EORTC infectious diseases group trial XV. J Clin Oncol. 2013;31(9):1149–56. doi:10.1200/JCO.2012.45.8109.

    Article  CAS  PubMed  Google Scholar 

  53. Paul M, Dickstein Y, Borok S, Vidal L, Leibovici L. Empirical antibiotics targeting Gram-positive bacteria for the treatment of febrile neutropenic patients with cancer. Cochrane Database Syst Rev. 2014;1:CD003914. doi:10.1002/14651858.CD003914.pub3.

    PubMed  Google Scholar 

  54. Paul M, Soares-Weiser K, Grozinsky S, Leibovici L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev. 2003;3:CD003038. doi:10.1002/14651858.CD003038.

    PubMed  Google Scholar 

  55. Gudiol C, Tubau F, Calatayud L, Garcia-Vidal C, Cisnal M, Sanchez-Ortega I, et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother. 2011;66(3):657–63. doi:10.1093/jac/dkq494.

    Article  CAS  PubMed  Google Scholar 

  56. Marin M, Gudiol C, Garcia-Vidal C, Ardanuy C, Carratala J. Bloodstream infections in patients with solid tumors: epidemiology, antibiotic therapy, and outcomes in 528 episodes in a single cancer center. Medicine (Baltimore). 2014;93(3):143–9. doi:10.1097/MD.0000000000000026.

    Article  CAS  Google Scholar 

  57. Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European conference on infections in leukemia. Haematologica. 2013;98(12):1826–35. doi:10.3324/haematol.2013.091025.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Meidani M, Khorvash F, Abolghasemi H, Jamali B. Procalcitonin and quantitative C-reactive protein role in the early diagnosis of sepsis in patients with febrile neutropenia. South Asian J Cancer. 2013;2(4):216–9. doi:10.4103/2278-330X.119913.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Jimeno A, Garcia-Velasco A, del Val O, Gonzalez-Billalabeitia E, Hernando S, Hernandez R, et al. Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer. 2004;100(11):2462–9. doi:10.1002/cncr.20275.

    Article  CAS  PubMed  Google Scholar 

  60. Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K. The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection. 2008;36(5):396–407. doi:10.1007/s15010-008-7374-y.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Priscilla Chase Duran and Ana Martín of HealthCo (Madrid, Spain) have provided editorial assistance for the drafting of this manuscript which was funded by the Spanish Society of Medical Oncology (SEOM).

Author information

Authors and Affiliations

  1. Servicio de Oncología Médica, Hospital Universitario Virgen de Macarena, Avda. Doctor Fedriani, 3, 41071, Seville, Spain

    J. A. Virizuela & D. Vicente

  2. Servicio de Enfermedades Infecciosas, Hospital Universitari de Bellvitge-IDIBELL, Universitat de Barcelona, Barcelona, Spain

    J. Carratalà & C. Gudiol

  3. Unidad de Enfermedades Infecciosas, Hospital Universitario 12 de Octubre, Madrid, Spain

    J. M. Aguado & M. Lizasoain

  4. Unidad de Enfermedades Infecciosas, Hospital Universitari i Politècnic La Fe, Valencia, Spain

    M. Salavert

  5. Servicio de Oncología Médica, Hospital Universitari Vall d’Hebron, Barcelona, Spain

    M. Ruiz

  6. Unidad de Enfermedades Infecciosas, Hospital Universitari Vall d’Hebron, Barcelona, Spain

    I. Ruiz

  7. Laboratori de Microbiologia, Centre de Diagnòstic Biomèdic (CDB), ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain

    F. Marco

  8. Servicio de Oncología Médica, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain

    P. Jiménez-Fonseca

  9. Institut Català d’Oncologia, Barcelona, Spain

    C. Gudiol

  10. Servicio de Oncología Médica, Hospital Universitario de Guadalajara, Guadalajara, Spain

    J. Cassinello

  11. Servicio de Hematología y Oncología Médica, Hospital General Universitario Morales Meseguer, Murcia, Spain

    A. Carmona-Bayonas

  12. Unidad de Enfermedades Infecciosas, Hospital Universitario Virgen del Rocío, Seville, Spain

    M. Aguilar

  13. Servicio de Oncología Médica, Hospital Clínico Universitario de Salamanca, Salamanca, Spain

    J. J. Cruz

Authors
  1. J. A. Virizuela
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Carratalà
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. M. Aguado
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Vicente
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Salavert
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Ruiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I. Ruiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F. Marco
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Lizasoain
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P. Jiménez-Fonseca
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. C. Gudiol
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J. Cassinello
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A. Carmona-Bayonas
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. M. Aguilar
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. J. J. Cruz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. A. Virizuela.

Ethics declarations

Conflict of interest

The authors state that at the time of writing and revising the text, they were unaware of the name of the laboratories that have provided economic support for this project, and that said support has, therefore, had no bearing on the content of this article.

Ethical statement

The study has been performed in accordance with the ethical standards of the Declaration of Helsinki and its later amendments. This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent statement

Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.

Additional information

Jordi Carratalà, José María Aguado, Miguel Salavert, Francesc Marco, Manuel Lizasoain, Carlota Gudiol, Manuela Aguilar: Members of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). Juan Antonio Virizuela, David Vicente, Maribel Ruiz, Paula Jiménez Fonseca, Javier Cassinello, Alberto Carmona-Bayonas, Juan Jesús Cruz: Members of the Spanish Society of Medical Oncology (SEOM).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Virizuela, J.A., Carratalà, J., Aguado, J.M. et al. Management of infection and febrile neutropenia in patients with solid cancer. Clin Transl Oncol 18, 557–570 (2016). https://doi.org/10.1007/s12094-015-1442-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-015-1442-4

Keywords

Search

Navigation